NAVAMEDIC (NAVA.OL) Stock Fundamental Analysis
Europe - Euronext Oslo - OSL:NAVA - NO0010205966 - Common Stock
20.8 NOK
-0.1 (-0.48%)
We assign a fundamental rating of 4 out of 10 to NAVA. NAVA was compared to 55 industry peers in the Pharmaceuticals industry. NAVA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NAVA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year NAVA has reported negative net income.
In the past year NAVA had a positive cash flow from operations.
In multiple years NAVA reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: NAVA reported negative operating cash flow in multiple years.
1.2 Ratios
NAVA's Return On Assets of -6.84% is on the low side compared to the rest of the industry. NAVA is outperformed by 67.27% of its industry peers.
NAVA has a Return On Equity of -15.33%. This is in the lower half of the industry: NAVA underperforms 69.09% of its industry peers.
Looking at the Return On Invested Capital, with a value of 5.11%, NAVA is in line with its industry, outperforming 43.64% of the companies in the same industry.
NAVA had an Average Return On Invested Capital over the past 3 years of 10.14%. This is below the industry average of 14.56%.
The 3 year average ROIC (10.14%) for NAVA is well above the current ROIC(5.11%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.84% | ||
| ROE | -15.33% | ||
| ROIC | 5.11% |
ROA(3y)1.27%
ROA(5y)-0.47%
ROE(3y)1.61%
ROE(5y)-1.5%
ROIC(3y)10.14%
ROIC(5y)N/A
1.3 Margins
With a Operating Margin value of 4.03%, NAVA is not doing good in the industry: 61.82% of the companies in the same industry are doing better.
NAVA's Operating Margin has improved in the last couple of years.
With a Gross Margin value of 37.23%, NAVA is not doing good in the industry: 74.55% of the companies in the same industry are doing better.
NAVA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.03% | ||
| PM (TTM) | N/A | ||
| GM | 37.23% |
OM growth 3Y13.14%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y5.2%
2. Health
2.1 Basic Checks
NAVA has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, NAVA has more shares outstanding
Compared to 5 years ago, NAVA has more shares outstanding
NAVA has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.48 indicates that NAVA is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.48, NAVA is in line with its industry, outperforming 49.09% of the companies in the same industry.
NAVA has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as NAVA would need 2.78 years to pay back of all of its debts.
NAVA has a Debt to FCF ratio of 2.78. This is in the better half of the industry: NAVA outperforms 70.91% of its industry peers.
NAVA has a Debt/Equity ratio of 0.33. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.33, NAVA is doing good in the industry, outperforming 65.45% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 2.48 |
ROIC/WACC0.64
WACC7.95%
2.3 Liquidity
NAVA has a Current Ratio of 1.30. This is a normal value and indicates that NAVA is financially healthy and should not expect problems in meeting its short term obligations.
NAVA has a Current ratio (1.30) which is comparable to the rest of the industry.
NAVA has a Quick Ratio of 1.30. This is a bad value and indicates that NAVA is not financially healthy enough and could expect problems in meeting its short term obligations.
NAVA's Quick ratio of 0.71 is on the low side compared to the rest of the industry. NAVA is outperformed by 76.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.71 |
3. Growth
3.1 Past
The earnings per share for NAVA have decreased strongly by -236.79% in the last year.
The Revenue has decreased by -3.67% in the past year.
Measured over the past years, NAVA shows a very strong growth in Revenue. The Revenue has been growing by 23.00% on average per year.
EPS 1Y (TTM)-236.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-107.47%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y24.05%
Revenue growth 5Y23%
Sales Q2Q%-12.17%
3.2 Future
Based on estimates for the next years, NAVA will show a very strong growth in Earnings Per Share. The EPS will grow by 31.39% on average per year.
The Revenue is expected to grow by 12.79% on average over the next years. This is quite good.
EPS Next Y-132.32%
EPS Next 2Y-3.96%
EPS Next 3Y17.35%
EPS Next 5Y31.39%
Revenue Next Year11.11%
Revenue Next 2Y18.62%
Revenue Next 3Y17.41%
Revenue Next 5Y12.79%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NAVA. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 17.43, which indicates a rather expensive current valuation of NAVA.
NAVA's Price/Forward Earnings is on the same level as the industry average.
NAVA is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 34.42, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 17.43 |
4.2 Price Multiples
NAVA's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. NAVA is cheaper than 74.55% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, NAVA is valued a bit cheaper than the industry average as 78.18% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.47 | ||
| EV/EBITDA | 9.07 |
4.3 Compensation for Growth
A more expensive valuation may be justified as NAVA's earnings are expected to grow with 17.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.96%
EPS Next 3Y17.35%
5. Dividend
5.1 Amount
No dividends for NAVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:NAVA (11/24/2025, 2:10:38 PM)
20.8
-0.1 (-0.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners23.77%
Inst Owner ChangeN/A
Ins Owners12.68%
Ins Owner ChangeN/A
Market Cap498.78M
Revenue(TTM)523.56M
Net Income(TTM)-33.20M
Analysts82.86
Price Target36.72 (76.54%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.23%
Min Revenue beat(2)-7.18%
Max Revenue beat(2)-5.28%
Revenue beat(4)0
Avg Revenue beat(4)-8.08%
Min Revenue beat(4)-17.93%
Max Revenue beat(4)-1.92%
Revenue beat(8)2
Avg Revenue beat(8)-3.62%
Revenue beat(12)4
Avg Revenue beat(12)-1.68%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10%
PT rev (3m)1.69%
EPS NQ rev (1m)-118.33%
EPS NQ rev (3m)-118.33%
EPS NY rev (1m)-192.86%
EPS NY rev (3m)-156.55%
Revenue NQ rev (1m)0.14%
Revenue NQ rev (3m)0.14%
Revenue NY rev (1m)-1.37%
Revenue NY rev (3m)2.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 17.43 | ||
| P/S | 0.95 | ||
| P/FCF | 12.47 | ||
| P/OCF | 11.49 | ||
| P/B | 2.3 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.07 |
EPS(TTM)-1.91
EYN/A
EPS(NY)1.19
Fwd EY5.74%
FCF(TTM)1.67
FCFY8.02%
OCF(TTM)1.81
OCFY8.7%
SpS21.83
BVpS9.03
TBVpS-1.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.84% | ||
| ROE | -15.33% | ||
| ROCE | 6.63% | ||
| ROIC | 5.11% | ||
| ROICexc | 5.98% | ||
| ROICexgc | 90.24% | ||
| OM | 4.03% | ||
| PM (TTM) | N/A | ||
| GM | 37.23% | ||
| FCFM | 7.64% |
ROA(3y)1.27%
ROA(5y)-0.47%
ROE(3y)1.61%
ROE(5y)-1.5%
ROIC(3y)10.14%
ROIC(5y)N/A
ROICexc(3y)12.6%
ROICexc(5y)N/A
ROICexgc(3y)98.8%
ROICexgc(5y)N/A
ROCE(3y)13.17%
ROCE(5y)N/A
ROICexgc growth 3Y90.11%
ROICexgc growth 5YN/A
ROICexc growth 3Y12.82%
ROICexc growth 5YN/A
OM growth 3Y13.14%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y5.2%
F-Score4
Asset Turnover1.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.15 | ||
| Cap/Depr | 8.34% | ||
| Cap/Sales | 0.65% | ||
| Interest Coverage | 2.91 | ||
| Cash Conversion | 69.98% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.71 | ||
| Altman-Z | 2.48 |
F-Score4
WACC7.95%
ROIC/WACC0.64
Cap/Depr(3y)19.25%
Cap/Depr(5y)40.99%
Cap/Sales(3y)0.55%
Cap/Sales(5y)0.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-236.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-107.47%
EPS Next Y-132.32%
EPS Next 2Y-3.96%
EPS Next 3Y17.35%
EPS Next 5Y31.39%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y24.05%
Revenue growth 5Y23%
Sales Q2Q%-12.17%
Revenue Next Year11.11%
Revenue Next 2Y18.62%
Revenue Next 3Y17.41%
Revenue Next 5Y12.79%
EBIT growth 1Y-55.6%
EBIT growth 3Y40.35%
EBIT growth 5YN/A
EBIT Next Year22.79%
EBIT Next 3Y32.76%
EBIT Next 5Y26.96%
FCF growth 1Y29.54%
FCF growth 3YN/A
FCF growth 5Y24.61%
OCF growth 1Y30.76%
OCF growth 3YN/A
OCF growth 5Y25.36%
NAVAMEDIC / NAVA.OL FAQ
Can you provide the ChartMill fundamental rating for NAVAMEDIC?
ChartMill assigns a fundamental rating of 4 / 10 to NAVA.OL.
What is the valuation status for NAVA stock?
ChartMill assigns a valuation rating of 3 / 10 to NAVAMEDIC (NAVA.OL). This can be considered as Overvalued.
What is the profitability of NAVA stock?
NAVAMEDIC (NAVA.OL) has a profitability rating of 3 / 10.